NGNE: Neurogene, Inc.
About
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
Current Value
$17.311 Year Return
Current Value
$17.311 Year Return
Key Details
Market Cap
$223.88M
P/E Ratio
-3.83
1Y Stock Return
32.95%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
1.6
Strategies that include NGNE
Stock's related to NGNE
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SNDX | 39.48% | $1.35B | +2.87% | 0.00% |
| ATSG | 36.70% | $1.44B | +39.23% | 0.00% |
| IART | 36.69% | $1.77B | -40.82% | 0.00% |
| ZNTL | 35.38% | $213.08M | -71.11% | 0.00% |
| ALEC | 32.79% | $377.04M | -19.46% | 0.00% |
| ALLO | 32.07% | $444.50M | -24.82% | 0.00% |
| THS | 31.87% | $1.72B | -17.36% | 0.00% |
| GSAT | 31.28% | $3.29B | +19.18% | 0.00% |
| ZYME | 31.10% | $1.03B | +79.68% | 0.00% |
| AVDL | 30.59% | $1.03B | -3.16% | 0.00% |
| CLRB | 30.10% | $65.31M | -24.77% | 0.00% |
| ANGI | 29.18% | $987.36M | -5.71% | 0.00% |
| ERII | 28.58% | $888.67M | -20.30% | 0.00% |
| IRON | 27.94% | $1.77B | +15.07% | 0.00% |
| KALV | 26.39% | $440.88M | +17.08% | 0.00% |
| SAGE | 26.38% | $300.36M | -74.61% | 0.00% |
| CRBU | 26.34% | $180.20M | -62.45% | 0.00% |
| LEN | 26.31% | $45.77B | +33.10% | 1.19% |
| AMBA | 26.29% | $2.44B | +7.82% | 0.00% |
| WSR | 26.15% | $738.93M | +33.24% | 3.37% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ALGM | -<0.01% | $3.59B | -31.01% | 0.00% |
| CNA | <0.01% | $13.16B | +23.03% | 3.61% |
| BP | <0.01% | $77.24B | -18.61% | 6.32% |
| FANG | -0.01% | $52.59B | +18.15% | 2.79% |
| VRSN | 0.03% | $17.13B | -16.16% | 0.00% |
| LHX | 0.03% | $46.20B | +29.18% | 1.91% |
| HLX | 0.04% | $1.60B | +13.04% | 0.00% |
| QNTM | -0.04% | $9.19M | -94.36% | 0.00% |
| USAP | -0.04% | $412.06M | +176.63% | 0.00% |
| PLTK | -0.06% | $3.14B | -3.00% | 3.59% |
| SWX | -0.06% | $5.68B | +33.56% | 3.16% |
| OR | 0.06% | $3.69B | +45.97% | 0.94% |
| ALT | 0.06% | $531.30M | +194.09% | 0.00% |
| KOS | -0.08% | $1.85B | -42.25% | 0.00% |
| PLMR | -0.08% | $2.84B | +79.77% | 0.00% |
| CRON | 0.08% | $776.06M | 0.00% | 0.00% |
| BYND | -0.08% | $318.19M | -22.91% | 0.00% |
| OCFT | -0.09% | $80.95M | -30.38% | 0.00% |
| ASH | -0.10% | $3.73B | -1.96% | 2.08% |
| KDP | 0.13% | $42.76B | -1.22% | 2.77% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| BTCT | -32.90% | $42.61M | +353.33% | 0.00% |
| MNOV | -21.83% | $93.19M | +2.15% | 0.00% |
| FLNG | -20.10% | $1.42B | -14.21% | 11.33% |
| CMTL | -18.79% | $84.44M | -76.16% | 0.00% |
| BCE | -18.04% | $24.91B | -30.63% | 10.69% |
| WHLM | -14.76% | $17.64M | -29.34% | 0.00% |
| SE | -13.68% | $60.12B | +197.12% | 0.00% |
| EDSA | -12.48% | $7.11M | -21.79% | 0.00% |
| ACRS | -11.92% | $327.87M | +415.67% | 0.00% |
| CNK | -11.87% | $4.09B | +138.59% | 0.00% |
| GFI | -11.67% | $13.42B | +10.06% | 2.63% |
| DRD | -11.53% | $854.61M | +13.63% | 2.30% |
| LEU | -10.79% | $1.12B | +33.82% | 0.00% |
| CCAP | -10.62% | - | - | 8.70% |
| SOC | -10.60% | $1.93B | +74.70% | 0.00% |
| TBRG | -10.57% | $244.47M | +52.66% | 0.00% |
| VUZI | -10.01% | $78.77M | -51.69% | 0.00% |
| ZTO | -9.49% | $12.58B | -4.71% | 4.73% |
| EE | -9.41% | $747.78M | +68.74% | 0.33% |
| OXBR | -9.27% | $19.05M | +178.18% | 0.00% |
ETF's related to NGNE
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| EFAA | 30.43% | $117.38M | 0% |
| IBB | 27.48% | $6.66B | 0.45% |
| XBI | 26.42% | $6.58B | 0.35% |
| DTD | 26.17% | $1.36B | 0.28% |
| XMMO | 26.06% | $2.99B | 0.34% |
| GNOM | 25.97% | $70.59M | 0.5% |
| RSPA | 25.96% | $273.87M | 0% |
| QDF | 25.64% | $1.88B | 0.37% |
| VB | 25.54% | $63.63B | 0.05% |
| ITEQ | 25.38% | $84.84M | 0.75% |
| XPH | 25.35% | $157.87M | 0.35% |
| PTH | 25.32% | $143.31M | 0.6% |
| ITB | 25.31% | $3.28B | 0.39% |
| IZRL | 25.22% | $102.75M | 0.49% |
| MDY | 25.11% | $24.14B | 0.24% |
| PY | 25.10% | $78.15M | 0.15% |
| PSC | 25.05% | $702.17M | 0.38% |
| SLYG | 25.05% | $3.69B | 0.15% |
| FNY | 25.01% | $372.31M | 0.7% |
| VXF | 24.93% | $21.54B | 0.06% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| UBND | 0.01% | $497.10M | 0.4% |
| UCON | -0.02% | $3.19B | 0.85% |
| BNDW | 0.06% | $854.64M | 0.05% |
| KCCA | -0.08% | $220.51M | 0.87% |
| UITB | 0.08% | $2.36B | 0.38% |
| SCHP | 0.09% | $11.70B | 0.03% |
| BOND | -0.09% | $5.01B | 0.58% |
| FLMI | 0.14% | $356.19M | 0.3% |
| TYA | -0.15% | $124.05M | 0.17% |
| ILTB | -0.15% | $604.33M | 0.06% |
| DBE | -0.15% | $50.13M | 0.77% |
| HYMU | 0.19% | $232.71M | 0.35% |
| SCHR | 0.28% | $9.97B | 0.03% |
| TIP | 0.29% | $16.12B | 0.19% |
| AGGH | 0.34% | $253.02M | 0.33% |
| OWNS | 0.43% | $124.17M | 0.3% |
| IBTF | 0.44% | $2.05B | 0.07% |
| DBC | -0.46% | $1.39B | 0.87% |
| DFCF | 0.50% | $5.80B | 0.17% |
| FMHI | -0.57% | $747.15M | 0.7% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -16.85% | $195.31M | 0.85% |
| CTA | -16.36% | $350.27M | 0.78% |
| BTAL | -14.94% | $388.04M | 1.43% |
| TPMN | -13.28% | $40.60M | 0.65% |
| TAIL | -10.10% | $67.98M | 0.59% |
| DFNM | -7.47% | $1.40B | 0.17% |
| YEAR | -7.15% | $1.13B | 0.25% |
| KMLM | -6.85% | $353.87M | 0.9% |
| IBMM | -6.81% | $391.28M | 0.18% |
| BAB | -6.58% | $1.06B | 0.28% |
| SMB | -6.54% | $266.77M | 0.07% |
| FMF | -6.54% | $244.61M | 0.95% |
| USDU | -6.25% | $201.97M | 0.5% |
| GOVZ | -6.03% | $313.00M | 0.1% |
| EDV | -5.93% | $3.88B | 0.06% |
| FMB | -5.89% | $2.03B | 0.65% |
| PWZ | -5.78% | $697.36M | 0.28% |
| CGSM | -5.53% | $514.53M | 0.25% |
| UUP | -5.44% | $309.25M | 0.77% |
| EQLS | -5.37% | $76.08M | 1% |
News
Yahoo
NEW YORK, November 18, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced third quarter 2024 financial results and highlighted recent corporate updates.
Yahoo
Neurogene stock collapsed, again, on Monday after the company scrapped the high dose of its experimental Rett Syndrome treatment.
Finnhub
NEW YORK, Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Neurogene Inc. . Such investors are advised to contact Danielle Peyton at...
Finnhub
NEW YORK — NEW YORK — Neurogene Inc. on Monday reported a loss of $20.2 million in its third quarter. The New York-based company said it had a loss of $1.19 per share. The results exceeded...
Finnhub
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates Announced positive interim clinical data with 1E15 vg dose of NGN-401 gene therapy trial for Rett...
Yahoo
NEW YORK, November 18, 2024--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of Rett syndrome.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.